Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 6-fluoro-1-methyl-7-(4-(5-methyl-2-oxo-1,3-dioxelen-4-yl)methyl-1-piperazinyl)-4-oxo-4h-(1,3)thiazeto(3,2-a)quinoline-3-carboxylic Acid
2. Nm 441
3. Nm-441
4. Nm441
1. 123447-62-1
2. Pruvel
3. Nm441
4. Quisnon
5. Nm-441
6. Prulifloxacin [inn]
7. Sword
8. Nm 441
9. Prulifloxacin (hydrochloride)
10. 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)piperazin-1-yl)-4-oxo-1,4-dihydro-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic Acid
11. J42298iesw
12. Nsc-759833
13. 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-yl]-4-oxo-1h-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic Acid
14. Ncgc00164615-01
15. Prulifloxacin 100 Microg/ml In Acetonitrile
16. Dsstox_cid_26480
17. Dsstox_rid_81651
18. Dsstox_gsid_46480
19. 1h,4h-(1,3)thiazeto(3,2-a)quinoline-3-carboxylic Acid, 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)-1-piperazinyl)-4-oxo-
20. 1h,4h-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic Acid, 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-1-piperazinyl]-4-oxo-
21. 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)piperazin-1-yl)-4-oxo-1h,4h-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic Acid
22. Ccris 7686
23. Cas-123447-62-1
24. Unii-j42298iesw
25. Pufloxacin Dioxolil
26. 6-fluoro-1-methyl-7-{4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-yl}-4-oxo-4h-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic Acid
27. Prulifloxacin [mi]
28. Prulifloxacin [jan]
29. Mls006011767
30. Prulifloxacin [mart.]
31. Prulifloxacin [who-dd]
32. Chembl422648
33. Nad-441a
34. Opt-99
35. Schembl1650794
36. Dtxsid0046480
37. Chebi:32071
38. Bcp12727
39. Hy-b0024
40. Tox21_112235
41. Bbl034010
42. Mfcd00864847
43. S2071
44. Stk626148
45. Akos005559236
46. Nm441;af 3013
47. Prulifloxacin (nm441, Af 3013)
48. Tox21_112235_1
49. Ac-2012
50. Af 3012
51. Db11892
52. Nsc 759833
53. Sb18983
54. Ncgc00164615-02
55. Ncgc00164615-03
56. (+-)-7-(4-((z)-2,3-dihydroxy-2-butenyl)-1-piperazinyl)-6-fluoro-1-methyl-4-oxo-1h,4h-(1,3)thiazeto(3,2-a)quinoline-3-carboxylic Acid, Cyclic Carbonate
57. As-13607
58. Smr000046722
59. Ft-0651733
60. P2058
61. F20576
62. 447p621
63. Prulifloxacin, >=98% (perchloric Acid Titration)
64. Sr-01000872596
65. Prulifloxacin, Antibiotic For Culture Media Use Only
66. Q-101929
67. Q3924793
68. Sr-01000872596-1
69. Brd-a92341659-001-01-6
70. 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-4-ium-1-yl]-4-oxo-1h-[1,3]thiazeto[3,2-a]quinoline-3-carboxylate
Molecular Weight | 461.5 g/mol |
---|---|
Molecular Formula | C21H20FN3O6S |
XLogP3 | 1 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 11 |
Rotatable Bond Count | 4 |
Exact Mass | 461.10568470 g/mol |
Monoisotopic Mass | 461.10568470 g/mol |
Topological Polar Surface Area | 125 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 931 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
Topoisomerase II Inhibitors
Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)
J - Antiinfectives for systemic use
J01 - Antibacterials for systemic use
J01M - Quinolone antibacterials
J01MA - Fluoroquinolones
J01MA17 - Prulifloxacin
Global Sales Information
Market Place
ABOUT THIS PAGE
A Prulifloxacin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Prulifloxacin, including repackagers and relabelers. The FDA regulates Prulifloxacin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Prulifloxacin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Prulifloxacin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Prulifloxacin supplier is an individual or a company that provides Prulifloxacin active pharmaceutical ingredient (API) or Prulifloxacin finished formulations upon request. The Prulifloxacin suppliers may include Prulifloxacin API manufacturers, exporters, distributors and traders.
click here to find a list of Prulifloxacin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Prulifloxacin DMF (Drug Master File) is a document detailing the whole manufacturing process of Prulifloxacin active pharmaceutical ingredient (API) in detail. Different forms of Prulifloxacin DMFs exist exist since differing nations have different regulations, such as Prulifloxacin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Prulifloxacin DMF submitted to regulatory agencies in the US is known as a USDMF. Prulifloxacin USDMF includes data on Prulifloxacin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Prulifloxacin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Prulifloxacin suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Prulifloxacin Drug Master File in Japan (Prulifloxacin JDMF) empowers Prulifloxacin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Prulifloxacin JDMF during the approval evaluation for pharmaceutical products. At the time of Prulifloxacin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Prulifloxacin suppliers with JDMF on PharmaCompass.
Prulifloxacin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Prulifloxacin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Prulifloxacin GMP manufacturer or Prulifloxacin GMP API supplier for your needs.
A Prulifloxacin CoA (Certificate of Analysis) is a formal document that attests to Prulifloxacin's compliance with Prulifloxacin specifications and serves as a tool for batch-level quality control.
Prulifloxacin CoA mostly includes findings from lab analyses of a specific batch. For each Prulifloxacin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Prulifloxacin may be tested according to a variety of international standards, such as European Pharmacopoeia (Prulifloxacin EP), Prulifloxacin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Prulifloxacin USP).
LOOKING FOR A SUPPLIER?